Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
American Journal of Hematology|March 30, 2026
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and SexNancy Gillis, Christelle Colin-Leitzinger, Yi-Han Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid LeukemiaIvana Gojo, Jan H Beumer, Keith W Pratz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 10, 2021
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid LeukemiaAnjali S Advani, William Tse, Hong Li, et al.
The New England Journal of Medicine|June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid LeukemiaGail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
JAMA Oncology|June 17, 2021
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19Michael A Thompson, Jeffrey P Henderson, Pankil K Shah, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Scientific Reports|July 23, 2021
Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemiaYoujin Wang, Weiyin Zhou, Lisa J McReynolds, et al.
Pageof 28